A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia

Inclusion Criteria: * Patients whose serum potassium value (local) at the Run-in period baseline is ≥5.5mEq/L, \< 6.5 mEq/L * Age 20 - 80 years old at informed consent * Patients who understand an overview of the study and voluntarily consented to participate in the study by documents. Main Exclusion Criteria: * Patients determined to require emergency treatment for hyperkalemia at the Run-in period baseline * Patients with poorly controlled blood pressure * Patients with heart failure in New York Heart Association Class IV * Patients who have experienced heart transplant, liver transplant or kidney transplant or who are predicted that the need for them will occur during the study * Patients who have taken any of the following medication within 7 days prior to the Run-in period baseline or currently administrated. 1. Sodium polystyrene sulfonate 2. Calcium polystyrene sulfonate 3. Sodium zirconium cyclosilicate hydrate 4. Potassium supplement * Patients with or who have experienced a severe swallowing disorder, moderate to severe gastroparesis, severe constipation, bowel obstruction, incarceration, abnormal post-operative bowel motility disorders or severe gastrointestinal disorders. In addition, patients who have experienced bariatric surgery or major gastrointestinal surgery (e.g., bowel resection). * Patients suspected to be with transient high potassium value.(ex. caused by dietary effects only)